Claims

1. A composition comprising a first and a second compound, wherein said first compound is an anti-inflammatory compound selected from the group consisting of a corticosteroid, FK506, tacrolimus, pimecrolimus, omalizumab, a recombinant human IFN-gamma, a microbial probiotic, a soluble IL-4 receptor, an anti–IL-5 monoclonal antibody, a TNF inhibitor, a chemokine receptor antagonist and a CLA inhibitor, alefacept and efalizumab and said second compound is a compound specifically targeting a bacterial cell, and wherein said second compound comprises;

- at least one cell wall binding domain specifically binding the peptidoglycan cell wall of said bacterial cell; and

- one or more enzymatic active domains exhibiting target bond specificity,

and wherein said second compound is a polypeptide that has at least 80% identity with SEQ ID NO: SEQ ID NO: 2, 4, 6, 8, 10, 12, 14, 16, 18, 20, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 52, 54, 56, 58, 60, 62, 64, 66, 68, 70, 72, 76, 78, 80, 82, 84, 86, 88, 90, 92, 94, 98 or 100; and/or said cell wall binding domain has at least 80% identity to any of SEQ ID NO: 4, 6 or 8; and/or wherein said one or more enzymatic active domains has at least 80% identity to any of SEQ ID NO: 10, 12, 14, 16, 18, 98 or 100.

2. A composition according to claim 1, wherein the second compound is specifically targeting a gram positive bacterial cell.

3. A kit of parts comprising:

a) a first vial containing a first mixture comprising a first compound as defined in claim 1; and,

b) a second vial containing a second mixture comprising a second compound as defined in claim 1 or 2; and optionally,

c) instructions for use, wherein the kit is for use in the manufacture of a medicament for preventing, delaying, and/or curing of dermatitis or eczema.

4. Use of a kit of parts according to claim 3, wherein the instructions for use comprise a dosage regime.

5. Use of a composition according to claim 1 or 2 in the manufacture of a medicament for preventing, delaying and/or curing of dermatitis or eczema.

6. Use of a composition according to claim 5 and/or use of a kit of parts according to claims 3 or 4, wherein said target bond is an essential bond in a peptidoglycan layer of said bacterial cell.

7. Use according to claim 6, wherein said one or more enzymatic active domains is selected from or is a combination of a domain of the group consisting of a cysteine, histidine dependent amidohydrolases/peptidase domain, an endopeptidase domain, an amidase domain and a glycosylhydrolase domain.

8. Use according to claim 5, wherein said gram positive bacterial cell is a *Staphylococcus*.

9. Use according to claim 8, wherein said cell wall binding domain originates from or is a homologue of a *Staphylococcus* phage endolysin and/or an *S. simulans* lysostaphin and/or an *S. capitis* ALE-1 bacteriocin.

10. Use according to any one of claims 4-9, wherein said second compound is a naturally occurring or mutant bacteriophage, a naturally occurring endolysin or a mutant polypeptide.

11. Use according to any one of claims 8-10, wherein said second compound is a recombinant polypeptide comprising a multiplicity of one or more enzymatic active domains exhibiting target bond specificity.